The biopharmaceutical company aTyr Pharma is entering a pivotal period for its lead therapeutic candidate, efzofitimod. Two major clinical and...

As spring approaches, Axsome Therapeutics finds itself at a critical juncture. The biopharmaceutical firm is strengthening its commercial footing with...

Uranium Energy Corp. presented its second-quarter fiscal 2026 results on March 10, revealing a mixed financial picture. The company benefits...

In a strategic move to bolster its core pharmaceutical business, Novartis has received expanded U.S. regulatory approval for its immunology...

Newmont Corporation is signaling to its investors that 2026 will be a year marked by volatility. The world's leading gold...

The Nemetschek Group has announced a proposal to its shareholders for a substantial increase in its annual dividend. The software...

The world's largest chemical company is advancing its historic corporate overhaul at a faster pace than initially projected. While a...

The Australian mining firm Syrah Resources finds itself navigating a complex landscape of contractual disputes and unfavorable trade rulings. While...

Austrian energy group OMV has delivered a robust annual performance, defying challenges in its traditional oil business through a decisive...

In March 2026, China's semiconductor industry publicly confirmed a long-held strategic objective: to develop its own EUV lithography system and...